



The Oncologist®

The International Peer-Reviewed Journal for the Practicing Oncologist/Hematologist

REVIEW ARTICLE

CANCER PREVENTION

- 1248 **Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis** CME
Ming Yin, Jie Zhou, Edward J. Gorak et al.
Commentary: Carlo La Vecchia, Cristina Bosetti

CLINICAL TRIAL RESULTS

- 1256 **Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study**
Giovanni Brandi, Francesco de Rosa, Valentina Agostini et al.

CHALLENGING CASES

- 1258 **Adjuvant Therapy for Adenocarcinoma of the Lung**
Rebecca Heist, Christopher G. Azzoli

ENDOCRINOLOGY

- 1262 **Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer** CME
Taofeek K. Owonikoko, Rajasree P. Chowdry, Zhengjia Chen et al.

GASTROINTESTINAL CANCER

- 1270 **Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas**
Kanwal P.S. Raghav, Aditya V. Shetty, Syed M.A. Kazmi et al.

GLOBAL HEALTH AND CENTER

- 1278 **Screen-and-Treat Approach to Cervical Cancer Prevention Using Visual Inspection With Acetic Acid and Cryotherapy**
Prima Paul, Jennifer L. Winkler, Rosario M. Bartolini et al.

- 1285 **Advancing Cervical Cancer Prevention in India: Implementation Science Priorities**
Suneeta Krishnan, Emily Madsen, Deborah Porterfield et al.

- 1298 **Breast Cancer in Young Women in Latin America**
Cynthia Villarreal-Garza, Christian Aguila, Maria C. Magallanes-Hoyos et al.

GYNECOLOGIC ONCOLOGY

- 1307 **Anti-Müllerian Hormone and Antral Follicle Count Reveal a Late Impairment of Ovarian Reserve in Patients Undergoing Low-Gonadotoxic Regimens for Hematological Malignancies**
Rossana Di Paola, Claudio Costantini, Cristina Tecchio et al.

OUTCOMES RESEARCH

- 1315 **Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit** CME
Siqing Fu, Lacey McQuinn, Aung Naing et al.

SYMPTOM MANAGEMENT AND SUPPORTIVE CARE

- 1321 **Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis**
Gary H. Lyman, Laurent Eckert, Yanxin Wang et al.

IN MEMORIAM

- 1332 **In Memoriam: Michael J. Haut**



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

The official journal of the



The Oncologist App

Genome & Co. v. Univ. of Chicago
PGR2019-00002
UNIV. CHICAGO EX. 2059

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.



COMMENTARY

1245 **Metformin: Are Potential Benefits on Cancer Risk Extended to Cancer Survival?**

Carlo La Vecchia, Cristina Bosetti (see article on page 1248)

CANCER PREVENTION

Section Editor: Powel H. Brown

CME 1248 **Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis**

Ming Yin, Jie Zhou, Edward J. Gorak, Fahd Quddus (see commentary on page 1245)

CLINICAL TRIAL RESULTS

Section Editors: Susan E. Bates, Antonio Tito Fojo

1256 **Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study**

Giovanni Brandi, Francesco de Rosa, Valentina Agostini, Stefania di Girolamo, Pietro Andreone, Luigi Bolondi, Carla Serra, Claudia Sama, Rita Golfieri, Annagiulia Gramenzi, Alessandro Cucchetti, Antonio Daniele Pinna, Franco Trevisani, Guido Biasco, for the ITALIAN LIVER CANCER (ITA.LI.CA) GROUP

CHALLENGING CASES

Section Editor: David P. Ryan

1258 **Adjuvant Therapy for a 3.9-cm Adenocarcinoma of the Lung**

Rebecca Heist, Chistopher G. Azzoli

ENDOCRINOLOGY

Section Editors: Herbert Chen, Stan B. Sidhu

CME 1262 **Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer**

Taofeek K. Owonikoko, Rajasree P. Chowdry, Zhengjia Chen, Sungjin Kim, Nabil F. Saba, Dong M. Shin, Fadlo R. Khuri

GASTROINTESTINAL CANCER

Section Editors: Richard M. Goldberg, Patrick G. Johnston, Peter J. O'Dwyer

1270 **Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas**

Kanwal P.S. Raghav, Aditya V. Shetty, Syed M.A. Kazmi, Nianxiang Zhang, Jeffrey Morris, Melissa Taggart, Keith Fournier, Richard Royal, Paul Mansfield, Cathy Eng, Robert A. Wolff, Michael J. Overman

The Oncologist (pISSN 1083-7159) and *The Oncologist* Online (eISSN 1549-490X) are published 12 times per year by AlphaMed Press, 318 Blackwell Street, Suite 260, Durham, NC 27701-2884 USA.

POSTMASTER: Send address changes to *The Oncologist*, P.O. Box 412, Congers, NY 10920-9914 USA.

2014 Subscription rates effective September 1, 2013: Individual: \$245 and resident/intern/fellow/student (with proof of status): \$98. Institutions: Tier 1: \$485; Tier 2: \$515; Tier 3: \$720; Tier 4: \$1102; Tier 5: contact AlphaMed Press for a quote. See www.theoncologist.com/subscriptions for tier descriptions. Subscribers in Canada and Mexico add \$75 per year, all other subscribers outside the U.S. add \$130 per year.

GLOBAL HEALTH AND CANCER

Section Editors: Felicia M. Knaul, Rifat Atun, Eduardo Cazap

1278 Screen-and-Treat Approach to Cervical Cancer Prevention Using Visual Inspection With Acetic Acid and Cryotherapy: Experiences, Perceptions, and Beliefs From Demonstration Projects in Peru, Uganda, and Vietnam

Proma Paul, Jennifer L. Winkler, Rosario M. Bartolini, Mary E. Penny, Trinh Thu Huong, Le Thi Nga, Edward Kumakech, Emmanuel Mugisha, Jose Jeronimo

1285 Advancing Cervical Cancer Prevention in India: Implementation Science Priorities

Suneeta Krishnan, Emily Madsen, Deborah Porterfield, Beena Varghese

1298 Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden

Cynthia Villarreal-Garza, Christian Aguila, Maria C. Magallanes-Hoyos, Alejandro Mohar, Enrique Bargalló, Abelardo Meneses, Eduardo Cazap, Henry Gomez, Lizbeth López-Carrillo, Yanin Chávarri-Guerra, Raúl Murillo, Carlos Barrios

GYNECOLOGIC ONCOLOGY

Section Editors: Dennis S. Chi, Peter G. Harper

1307 Anti-Müllerian Hormone and Antral Follicle Count Reveal a Late Impairment of Ovarian Reserve in Patients Undergoing Low-Gonadotoxic Regimens for Hematological Malignancies

Rossana Di Paola, Claudio Costantini, Cristina Tecchio, Gian Luca Salvagno, Rachele Montemezzi, Alessio Perandini, Giovanni Pizzolo, Stefano Zaffagnini, Massimo Franchi

OUTCOMES RESEARCH

Section Editors: Scott Ramsey, Bong-Min Yang

CME 1315 Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit

Siqing Fu, Lacey McQuinn, Aung Naing, Jennifer J. Wheler, Filip Janku, Gerald S. Falchook, Sarina A. Piha-Paul, Dennis Tu, Adrienne Howard, Apostolia Tsimberidou, Ralph Zinner, David S. Hong, Razelle Kurzrock

SYMPTOM MANAGEMENT AND SUPPORTIVE CARE

Section Editors: Eduardo Bruera, Russell K. Portenoy

1321 Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis

Gary H. Lyman, Laurent Eckert, Yanxin Wang, Hongwei Wang, Alexander Cohen

LETTERS TO THE EDITOR

1330 Comprehensive Geriatric Assessment and Adjustment of Cancer Treatment

Monique S. Slee-Valentijn, Andrea B. Maier

1331 In Reply

Nadine J. McCleary, Arti Hurria, Jeffrey Meyerhardt

IN MEMORIAM

1332 In Memoriam: Michael J. Haut

1334 Volume 18 Acknowledgments

1336 Volume 18 Author Index

EUROPEAN PERSPECTIVES



e29 Addressing Cancer Disparities in Europe: A Multifaceted Problem That Requires Interdisciplinary Solutions

Sean Duffy, Mike Richards, Peter Selby, Mark Lawler

Clinical Trial Results

Now accepting Phase I and Phase II trials for publication
ClinicalTrialResults.TheOncologist.com



CORRESPONDENCE

Editorial correspondence, including submissions for publication, letters to the Editor, and book reviews should be submitted to the Editors at www.ManuscriptSubmissions.TheOncologist.com.

Reflections: The editors encourage the submission of photography, artwork, poetry, and prose dealing with the thoughts, feelings, and deep concerns of caregivers, their cancer patients, and their loved ones. These should be submitted to the Editors.

Information for Authors and associated submission materials may be found at www.TheOncologist.com.

Cover Art: **Oriental Poppy**[®] by *Bernique Longley*. Laudanum, or tincture of opium, was for many decades the only “treatment” for cancer in the Old West; the *Oriental Poppy* has, therefore, been chosen as the Journal’s icon.

The Oncologist (pISSN 1083-7159) and *The Oncologist* online (eISSN 1549-490X) are published 12 times per year by AlphaMed Press, 318 Blackwell Street, Suite 260, Durham, NC 27701-2884.

Postmaster

Send all address changes to *The Oncologist*, P.O. Box 412, Congers, NY 10920-9914 USA.

Editorial Correspondence

AlphaMed Press
318 Blackwell St, Ste 260
Durham, NC 27701
Tel: (919) 680-0011
Fax: (919) 680-4411
E-mail: EditorialOffice@TheOncologist.com

Information for Authors

Please see the complete Information for Authors, available online at www.TheOncologist.AlphaMedPress.com or by contacting the Editorial Office at Authors.TheOncologist.com

Supplements

Proposals for journal supplements covering clinical investigations and research developments, seminars, workshops, and conferences are invited for publication consideration.
Contact Editors@TheOncologist.com

Reprints and Permissions

AlphaMed Press – *The Oncologist*
318 Blackwell St, Ste 260
Durham, NC 27701
Tel: (919) 680-0011
Fax: (919) 680-4411
E-mail: Reprints@AlphaMedPress.com

Copyright

©2013 AlphaMed Press. *The Oncologist*® (pISSN 1083-7159) and *The Oncologist*® Online (eISSN 1549-490X) and all contributions included therein are protected by copyright. All rights are reserved under United States and international copyright laws and other applicable laws and conventions. No copyright is claimed in any original work created by agencies or employees of the United States government. No part of this publication may be reproduced or transmitted in any form without the prior written consent of AlphaMed Press or Copyright Clearance Center, www.copyright.com, e-mail: info@copyright.com. Certain provisions of the Copyright Act of 1976, as amended, respecting fair use and reproduction by libraries and archives, 17 U.S.C. §§ 107 and 108, may be applicable. All other permission requests should be directed to the Publisher. Please submit your request in writing to AlphaMed Press at Permissions@AlphaMedPress.com.

Disclaimer

While the publisher and Editorial Board make every effort to see that no inaccurate or misleading data, opinion, or statement appear in this journal, they wish to state that the data and opinions in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publisher, the Editorial Board, and their respective employees, officers, and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion, or statement. While every effort is made to ensure drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage described within this journal should only be followed in conjunction with the drug manufacturer's own published literature. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. This is particularly serious if the agent to be administered is a new one or one that is infrequently used. Because of the uniqueness of each patient and the need to take into account a number of concurrent considerations, this information should be used by physicians only as a general guide to determining the best treatment for each patient.



The Oncologist®

The official journal of the Society for Translational Oncology

The Oncologist® Journal is regularly indexed by Index Medicus/MEDLINE, EMBASE/Excerpta Medica, Compendex, Geobase, Chemical Abstracts, Biology Digest, Cumulative Index to Nursing and Allied Health Literature print index and database, Science Citation Index-Expanded, ISI Alerting Services, Current Contents/Clinical Medicine.

The Oncologist® is printed in the United States of America on paper that meets ANSI/NISO Z39.48-1992 requirements and adheres to library/archival stability.

Business-to-Business Opportunities

Marty J. Murphy, 3rd
VP, Publishing Technology & Business Development
AlphaMed Press
318 Blackwell St, Ste 260
Durham, NC 27701
Tel: (919) 200-3727
Fax: (919) 287-2749
E-mail: Marty3rd@AlphaMedPress.com

Advertising Information

Tim Wolfinger
Pharmaceutical Media, Inc.
30 E 33rd St, 4th floor
New York, NY 10016
Tel: (212) 904-0379
Fax: (212) 685-6126
E-mail: twolfinger@pminy.com

Subscriptions/Access Issues/Customer Service

The Oncologist
PO Box 412
Congers, NY 10920-9914
Tel: (800) 206-9850 / (845) 267-3079
Fax: (845) 267-3478
E-mail: TheOncologist@cambeywest.com

Claims

When claims for undelivered or damaged issues are made within three months of publication of an issue, a complimentary replacement will be provided.

2014 Subscription Rates

Subscription rates are \$245* for individuals or \$98 for resident/intern/fellow/student (with proof of status).

Institutional Rates

Tier 1 (Institutional Print Only) - \$485*

Online Only

- Tier 2 - \$432.50
- Tier 3 - \$631
- Tier 4 - \$937.50
- Tier 5, multi-sites, and licenses - contact publisher for pricing

Print & Online*

- Tier 2 - \$515*
- Tier 3 - \$720*
- Tier 4 - \$1102*
- Tier 5, multi-sites, and licenses - contact publisher for pricing*

* Subscribers in Canada or Mexico add \$75 per year, all other subscribers outside the U.S. add \$130 per year.

Back Issue Orders

Subject to their availability, price for single or back issues is \$40 (U.S.) or \$45 (outside the U.S.) and must be prepaid.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.